Literature DB >> 22209701

Striking differences in proconvulsant-induced alterations of seizure threshold in two rat models.

Marion Bankstahl1, Jens P Bankstahl, Petra Bloms-Funke, Wolfgang Löscher.   

Abstract

During drug development, seizure threshold tests are widely used to identify potential proconvulsant activity of investigational drugs. The most commonly used tests in this respect are the timed intravenous pentylenetetrazole (PTZ) infusion seizure test and the maximal electroshock seizure threshold (MEST) test in mice or rats. To our knowledge, no study is available in which proconvulsant drug activities in these models are directly compared, which prompted us to perform such experiments in male Wistar rats. Five drugs with reported proconvulsant activity were tested in the two models: d-amphetamine, chlorpromazine, caffeine, theophylline, and tramadol. Furthermore, the anticonvulsant drug phenobarbital was included in the experiments. While phenobarbital exerted anticonvulsant activity in both models, the five proconvulsant drugs markedly differed in their effects. In the dose range tested, d-amphetamine significantly lowered the PTZ seizure threshold but increased the MEST, caffeine and theophylline did not alter the PTZ seizure threshold but decreased the MEST, and tramadol reduced the PTZ threshold but increased the MEST. These marked differences between seizure threshold tests are most likely a consequence of the mechanisms underlying seizure induction in these tests. Our data indicate that using only one seizure threshold model during preclinical drug development may pose the risk that potential proconvulsant activity of an investigational drug is overseen. However, the label "proconvulsant" may be misleading if such activity only occurs at doses high above the therapeutic range, but the drug is not proconvulsant or even exerts anticonvulsant effects at lower, therapeutically relevant doses.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22209701     DOI: 10.1016/j.neuro.2011.12.011

Source DB:  PubMed          Journal:  Neurotoxicology        ISSN: 0161-813X            Impact factor:   4.294


  6 in total

1.  Proconvulsant actions of intrahippocampal botulinum neurotoxin B in the rat.

Authors:  S Bröer; D Zolkowska; M Gernert; M A Rogawski
Journal:  Neuroscience       Date:  2013-07-29       Impact factor: 3.590

2.  OV329, a novel highly potent γ-aminobutyric acid aminotransferase inactivator, induces pronounced anticonvulsant effects in the pentylenetetrazole seizure threshold test and in amygdala-kindled rats.

Authors:  Malte Feja; Sebastian Meller; Lillian S Deking; Edith Kaczmarek; Matthew J During; Richard B Silverman; Manuela Gernert
Journal:  Epilepsia       Date:  2021-10-07       Impact factor: 5.864

Review 3.  [Convulsive crisis in Tramadol and caffeine abusers: about 8 cases and review of the literature].

Authors:  Djibo Douma Maiga; Houdou Seyni; Amadou Sidikou; Alfazazi Azouma
Journal:  Pan Afr Med J       Date:  2012-10-03

4.  Advantages of repeated low dose against single high dose of kainate in C57BL/6J mouse model of status epilepticus: behavioral and electroencephalographic studies.

Authors:  Karen Tse; Sreekanth Puttachary; Edward Beamer; Graeme J Sills; Thimmasettappa Thippeswamy
Journal:  PLoS One       Date:  2014-05-06       Impact factor: 3.240

5.  Neuropharmacological characterization of the oneirogenic Mexican plant Calea zacatechichi aqueous extract in mice.

Authors:  Maciej Sałaga; Jakub Fichna; Katarzyna Socała; Dorota Nieoczym; Mateusz Pieróg; Marta Zielińska; Anna Kowalczuk; Piotr Wlaź
Journal:  Metab Brain Dis       Date:  2016-01-28       Impact factor: 3.584

6.  Seizure suppression through manipulating splicing of a voltage-gated sodium channel.

Authors:  Wei-Hsiang Lin; Miaomiao He; Richard A Baines
Journal:  Brain       Date:  2015-02-12       Impact factor: 13.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.